Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HUTCHMED (China) (HCM) Cash & Equivalents: 2014-2022

Historic Revenue - Interest and Investment Income for HUTCHMED (China) (HCM) over the last 2 years, with Dec 2021 value amounting to $1.4 billion.

  • HUTCHMED (China)'s Revenue - Interest and Investment Income rose 40.85% to $1.8 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $5.4 billion, marking a year-over-year increase of 12.16%. This contributed to the annual value of $1.4 billion for FY2021, which is 89.56% up from last year.
  • According to the latest figures from FY2021, HUTCHMED (China)'s Revenue - Interest and Investment Income is $1.4 billion, which was up 89.56% from $724.1 million recorded in FY2020.
  • HUTCHMED (China)'s 5-year Cash & Equivalents high stood at $377.5 million for FY2021, and its period low was $86.0 million during FY2018.
  • Its 3-year average for Cash & Equivalents is $308.8 million, with a median of $313.3 million in 2022.
  • Data for HUTCHMED (China)'s Revenue - Interest and Investment Income shows a peak YoY spiked of 89.56% (in 2021) over the last 5 years.
  • HUTCHMED (China)'s Revenue - Interest and Investment Income (Yearly) stood at $724.1 million in 2020, then skyrocketed by 89.56% to $1.4 billion in 2021.